News

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The…
Read More...

Pacira Pharmaceuticals and MyoScience announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira. MyoScience currently markets the ioveraº system, a…
Read More...

ReForm Biologics announced a collaboration with Astellas Pharma Inc. to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform…
Read More...

Bayer has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide for the treatment of patients with…
Read More...

AnTolRx announced that Pfizer Inc. has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program.…
Read More...

Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North…
Read More...

Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the…
Read More...

Medexus Pharmaceuticals Inc. announced that it has entered into a licensing agreement with photonamic GmbH & Co. KG for the exclusive rights to market and distribute Gliolan in…
Read More...

Biogen announced that it has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on…
Read More...

NantKwest and ProMab Biotechnologies announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with…
Read More...

Apellis Pharmaceuticals announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the…
Read More...

Pfenex Inc. and Alvogen Ltd. announced entering into agreements expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary…
Read More...

Third Rock Ventures announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines. The company has secured an initial investment…
Read More...

AbCellera announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications. AbCellera will generate panels of…
Read More...

Abpro and NJCTTQ announced that they have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in-class T-cell engagers.…
Read More...

Sarepta Therapeutics announced that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for…
Read More...

PAREXEL International Corporation announced several new appointments that will enhance the company’s oncology expertise as oncology trials grow in number and complexity. First, PAREXEL…
Read More...

PharmOptima, a member of Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) arm of Genesis Biotechnology Group (GBG), and Ophthy-DS, a preclinical…
Read More...

The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a partnership…
Read More...